York Pharma Share Discussion Threads

[slapdash] 14/1/2009 15:57

bust soon one would suspect.... hmmm all the brokers claimed this was worth loads of money.... but Sadler was always a bit of a character with a history...

Slap

[bignads] 14/1/2009 12:58

After doing some research on Fortress Capital Corp, I note that they are termed a vulture capital company that specialises in distressed assets. They are often referred to as a lender of last resort...! Not particularly promising.

[kiki14p] 14/1/2009 10:37

"However the company continues discussions with Solvay and is exploring alternative ways to raise finance to reaquire the brands".

This IMHO is now fundamental to York's long term future. Hopefully we can see a return to banks being prepared to lend and York surviving long enough to reaquire these brands in the not to distant future. It appears that Solvay bent over backwards to keep the deal alive in though York owed them €11.5m. Hopefully Solvay will remain patient and York can secure funding elsewhere.

[bignads] 14/1/2009 10:29

Maybe this is not so bad after all - the companies are in talks to reacquire the Solvey assets so that's not dead in the water, and the strategic review is a good idea given the situation. Furthermore, the purchase price may actually be lower than previously because the negotiations will take place post crunch. Ho hum, just trying to look on the bright side!

[jpendle] 14/1/2009 10:03

Completely incompetent management - share price didn't benefit from the deal announcement but has crashed as it failed.

How can they unraved to sales - and what about any investment YRk made during their periond of control


Where does the strategic review take us - they may have spent all their cask now - no wonder the market ignores the shares.

Even if the company announces good news over the coming months it will now benefit the share price because it will have a large ? mark over it - directors need changing before we can move on.

[bignads] 14/1/2009 08:59

How can the company announce completion of an acquisition in an RNS and then some three months later say that "well, actually, it wasn't exactly completed, as our main lender hadn't agreed to the revised conditions" - what an idiot Terry Sadler is. That was surely a grossly negligent statement.

[bignads] 14/1/2009 08:33

Yep, that is truely disasterous. THe company is very badly managed in my opinion. A strategic review is just what the company needs at the moment. May as well kiss this share goodbye.

[roorontev] 14/1/2009 08:07

Worry not Nobby will be along shortly to spin this "Great News"......

[kiki14p] 14/1/2009 08:02

Not looking good... no acquisition of Solvay products hence a loss of c£8 million revenues, aborted acquisition costs, and the release of York's sales force. What a disaster!!

[bignads] 05/1/2009 15:49

Happy New Year All. Looking forward to seeing what 2009 has in store for this company...Should find out what the prospects for the rest of the year are pretty soon, with the results due on 23 Jan.

[handycam] 23/12/2008 12:00

Trust me on this, it is offered in as many as you want. Shouldn't be using the word 'hopefully' with investments.

[bignads] 23/12/2008 11:44

Interesting that you can't buy any more YRK way below the official offer anymore - I picked some more up yesterday for 13.9, but the offer is now all the way up at 16.99, so buyers have obviously bought out all the MMs holdings for the time being. Means any more buying will start to see the spread tighten and hopefully we'll be on our way North again. It's about time!

[bignads] 23/12/2008 11:29

Wetdream - not yet, though if Abasol gets approved, the analysts valuations suggest that that scenario would be possible. It all hinges on the MHRA getting out of bed and finally taking a decision on that application...

[wetdream] 22/12/2008 16:46

Either way, it won't be YRK taking over Sincalir.

[handycam] 22/12/2008 13:46

Incorrect, my friend.

'Total Voting Rights


For the purposes of the Financial Services Authority's Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 57,082,186

And plus 4m since that announcement of 05 08 08.

61 x 15p = £9.15m

Sinclair:

'5. Earnings per share

The calculation of basic earnings per ordinary share is based on a profit of £
54,000 (2007 - loss of £73,000) and on 145,579,027 ordinary shares (2007 -
134,904,994) being the weighted average number of ordinary shares in issue
during the year.'

145 x 16.875p = £24.4m


For the record, Sinclair is two and two-thirds as big.

[wetdream] 22/12/2008 11:21

Current Sinclair mkt cap 4 times YRK.

[handycam] 22/12/2008 11:12

Sinclair and York are two very similar peas in a pod, though the former has a reasonable business it would seem. Share price trajectories are carbon copies.

[bignads] 22/12/2008 10:26

Good news again today. This company is really putting in place some decent infrastructure and agreements. Should have a very positive effect on revenues. If we weren't in the middle of an economic scare, the share price would probably be measured in pounds not pence.

Even so, given the delay, the abasol news has to come one way or another in the next few months. If you think the UK authorities are going to give the green light, then we are looking at a 200-300 percent rerating in that period. If we get bad news, then this could go down to 7 or 8 pence. In my view a pretty good risk-return.

[topvest] 22/12/2008 09:28

They have remembered Abasol...maybe it's not dead in the water.

[wetdream] 22/12/2008 09:08

but not 'When' in 2009!

However, useful tie up with Sinclair.
Looks like TS's having to work hard to get decent content for the January investor presentation.

[smelleroo] 22/12/2008 08:11

v interesting:

anticipated commercialisation of Abasol in the UK in 2009

smell

[roorontev] 22/12/2008 08:09

Jam anyone?.....

[kiki14p] 22/12/2008 08:08

Interesting tie-up with Sinclair Pharma today to co-promote each others products in the UK. TS even mentions Abasol! and anticipated commercialisation in 2009. So it hasn't been totally forgotten. Wonder if this is a precursor to a full merger with Sinclair?

[wetdream] 20/12/2008 13:10

smelleroo,

Only due to lack of appropriate clinical data.

Interesting point is whether YRK could sue the MHRA over 'excessive' delay.